The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Pharmacology of Ramelteon, a Selective MT1/MT2Receptor Agonist: A Novel Therapeutic Drug for Sleep Disorders
Open accessAbstract
An estimated one‐third of the general population is affected by insomnia, and this number is increasing due to more stressful working conditions and the progressive aging of society. However, current treatment of insomnia with hypnotics, gamma‐aminobutyric acid A (GABA A) receptor modulators, induces various side effects, including cognitive impairment, motor disturbance, dependence, tolerance, hangover, and rebound insomnia. Ramelteon (Rozerem; Takeda Pharmaceutical Company Limited, Osaka, Japan) is an orally active, highly selective melatonin MT 1/MT 2 receptor agonist. Unlike the sedative hypnotics that target GABA A receptor complexes, ramelteon is a chronohypnotic that acts on the melatonin MT 1 and MT 2 receptors, which are primarily located in the suprachiasmatic nucleus, the body's “master clock.” As such, ramelteon possesses the first new therapeutic mechanism of action for a prescription insomnia medication in over three decades. Ramelteon has demonstrated sleep‐promoting effects in clinical trials, and coupled with its favorable safety profile and lack of abuse potential or dependence, this chronohypnotic provides an important treatment option for insomnia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reppert, S. M., Weaver, D. R., & Ebisawa, T. (1994) · Neuron · doi:10.1016/0896-6273(94)90055-8 · Cited by 1,096
The Efficacy and Safety of Drug Treatments for Chronic Insomnia in Adults: A Meta-Analysis of RCTs
Buscemi, N., Vandermeer, B., Friesen, C., Bialy, L., Tubman, M., Ospina, M., Klassen, T. P., & Witmans, M. (2007) · Journal of General Internal Medicine · doi:10.1007/s11606-007-0251-z · Cited by 448 · cited 1×
“A number of studies showed that zolpidem causes potent reduction of sleep latency in humans [11,14,77], suggesting that there might be a species difference in sleep induction by zolpidem.”
BackgroundHajak, G., Müller, W. E., Wittchen, H. U., Pittrow, D., & Kirch, W. (2003) · Addiction · doi:10.1046/j.1360-0443.2003.00491.x · Cited by 404
Melatonin treatment for age-related insomnia
Zhdanova, I. V., Wurtman, R. J., Regan, M. M., Taylor, J. A., Shi, J. P., & Leclair, O. U. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.10.7901 · Cited by 308
Griffiths, R. R., Sannerud, C. A., Ator, N. A., & Brady, J. V. (1992) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)11429-8 · Cited by 112
Benefit-Risk Assessment of Zaleplon in the Treatment of Insomnia
Barbera, J., & Shapiro, C. (2005) · Drug Safety · doi:10.2165/00002018-200528040-00003 · Cited by 51
Cited by
Dubocovich, M. L., Delagrange, P., Krause, D. N., Sugden, D., Cardinali, D. P., & Olcese, J. (2010) · Pharmacological Reviews · doi:10.1124/pr.110.002832 · Cited by 621
Interventions for preventing delirium in hospitalised non-ICU patients
Siddiqi, N., Harrison, J. K., Clegg, A., Teale, E. A., Young, J., Taylor, J., & Simpkins, S. A. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005563.pub3 · Cited by 619
Preventive Effects of Ramelteon on Delirium: A Randomized Placebo-Controlled Trial
Hatta, K., Kishi, Y., Wada, K., Takeuchi, T., Odawara, T., Usui, C., & Nakamura, H. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.3320 · Cited by 369
Dietary Sources and Bioactivities of Melatonin
Meng, X., Li, Y., Li, S., Zhou, Y., Gan, R.-Y., Xu, D.-P., & Li, H.-B. (2017) · Nutrients · doi:10.3390/nu9040367 · Cited by 362
Melatonin and its analogs in insomnia and depression
Cardinali, D. P., Srinivasan, V., Brzezinski, A., & Brown, G. M. (2012) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2011.00962.x · Cited by 353
Metadata
- Authors
- Miyamoto, M.
- Venue
- CNS Neuroscience & Therapeutics
- Publisher
- Wiley
- Published
- 2009-02-13
- Volume
- 15
- Issue
- 1
- Pages
- 32-51
- ISSN
- 1755-5930 (ISSN-L)
- 1755-5949
- OpenAlex
- W2041347130
- Cited by
- 169
- References
- 7
- FWCI
- 3.84
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacology of Ramelteon, a Selective MT1/MT2Receptor Agonist: A Novel Therapeutic Drug for Sleep Disorders. https://app.cochat.ai/papers/10.1111/j.1755-5949.2008.00066.x
- The paper
- Miyamoto, M. (2009). Pharmacology of Ramelteon, a Selective MT1/MT2Receptor Agonist: A Novel Therapeutic Drug for Sleep Disorders. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/j.1755-5949.2008.00066.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.